SCHEMBL4467679

SCHEMBL4467679

Cc1c(O)c(C(C)C)cc2c1[C@@H](O)CC1(CCC1)O2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 9/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
PTGES O14684 2/20 0.32
PNLIP P16233 2/20 0.32
GGPS1 O95749 1/20 0.31
BCL9 O00512 3/20 0.30
CTNNB1 P35222 3/20 0.30
ALDH1A1 P00352 2/20 0.30
CYP3A4 P08684 2/20 0.30
MAPT P10636 2/20 0.30
HPGD P15428 2/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CYP2C9 P11712 1/20 0.30
ALOX12 P18054 1/20 0.30
GSTO1 P78417 1/20 0.30
KDM4E B2RXH2 1/20 0.30
USP2 O75604 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467746 1.00 FDPS (0.32) FDPSMEN1KMT2APTGESPNLIP
SCHEMBL4474666 1.00 FDPS (0.32) FDPSMEN1KMT2APTGESPNLIP
SCHEMBL4700773 0.87 CA1 (0.30) CA1CA2
SCHEMBL4464592 0.84 FDPS (0.36) FDPSMEN1KMT2APTGESPNLIP
SCHEMBL4459375 0.84 FDPS (0.33) FDPSMEN1KMT2APTGESPNLIP
SCHEMBL4469994 0.84 MEN1 (0.34) MEN1KMT2A
SCHEMBL5268555 0.83 MEN1 (0.41) MEN1KMT2ACA1CA2
SCHEMBL4459378 0.81 FDPS (0.32) FDPSMEN1KMT2APTGESPNLIP
SCHEMBL4481793 0.80 CA2 (0.33) MEN1KMT2AALDH1A1CA1CA2
SCHEMBL4473157 0.75 FDPS (0.34) FDPSMEN1KMT2APTGESPNLIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP claimed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO claimed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US claimed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 FDPS 259/4885MEN1 4420/4885KMT2A 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.